Mast Therapeutics Completes Acquisition of Aires Pharmaceuticals

San Diego-based Mast Therapeutics said yesterday that it has completed its acquisition of Aires Pharmaceuticals, the company developing treatments for pulmonary arterial hypertension. The deal is worth around $5.2M, and was announced earlier this month. Aires' primary product was AIR001, an intermittently nebulized formulation of nitrite used for reducing inflammation.